Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2011 3
2015 1
2016 1
2017 2
2021 2
Text availability
Article attribute
Article type
Publication date

Search Results

8 results
Results by year
Filters applied: . Clear all
Page 1
Genetic variation associated with bortezomib-induced peripheral neuropathy.
Favis R, Sun Y, van de Velde H, Broderick E, Levey L, Meyers M, Mulligan G, Harousseau JL, Richardson PG, Ricci DS. Favis R, et al. Among authors: ricci ds. Pharmacogenet Genomics. 2011 Mar;21(3):121-9. doi: 10.1097/FPC.0b013e3283436b45. Pharmacogenet Genomics. 2011. PMID: 21228734
Androgen receptor mutations in patients with castration-resistant prostate cancer treated with apalutamide.
Rathkopf DE, Smith MR, Ryan CJ, Berry WR, Shore ND, Liu G, Higano CS, Alumkal JJ, Hauke R, Tutrone RF, Saleh M, Chow Maneval E, Thomas S, Ricci DS, Yu MK, de Boer CJ, Trinh A, Kheoh T, Bandekar R, Scher HI, Antonarakis ES. Rathkopf DE, et al. Among authors: ricci ds. Ann Oncol. 2017 Sep 1;28(9):2264-2271. doi: 10.1093/annonc/mdx283. Ann Oncol. 2017. PMID: 28633425 Free PMC article. Clinical Trial.
Characterization of an Abiraterone Ultraresponsive Phenotype in Castration-Resistant Prostate Cancer Patient-Derived Xenografts.
Lam HM, McMullin R, Nguyen HM, Coleman I, Gormley M, Gulati R, Brown LG, Holt SK, Li W, Ricci DS, Verstraeten K, Thomas S, Mostaghel EA, Nelson PS, Vessella RL, Corey E. Lam HM, et al. Among authors: ricci ds. Clin Cancer Res. 2017 May 1;23(9):2301-2312. doi: 10.1158/1078-0432.CCR-16-2054. Epub 2016 Dec 19. Clin Cancer Res. 2017. PMID: 27993966 Free PMC article.
Association of Molecular Subtypes With Differential Outcome to Apalutamide Treatment in Nonmetastatic Castration-Resistant Prostate Cancer.
Feng FY, Thomas S, Saad F, Gormley M, Yu MK, Ricci DS, Rooney B, Brookman-May S, McCarthy S, Olmos D, Chowdhury S, Hadaschik B, Liu Y, Davicioni E, Smith MR, Small EJ. Feng FY, et al. Among authors: ricci ds. JAMA Oncol. 2021 Jul 1;7(7):1005-1014. doi: 10.1001/jamaoncol.2021.1463. JAMA Oncol. 2021. PMID: 34081076 Free PMC article.
Blood Biomarker Landscape in Patients with High-risk Nonmetastatic Castration-Resistant Prostate Cancer Treated with Apalutamide and Androgen-Deprivation Therapy as They Progress to Metastatic Disease.
Smith MR, Thomas S, Gormley M, Chowdhury S, Olmos D, Oudard S, Feng FY, Rajpurohit Y, Urtishak K, Ricci DS, Rooney B, Lopez-Gitlitz A, Yu M, Wyatt AW, Li M, Attard G, Small EJ. Smith MR, et al. Among authors: ricci ds. Clin Cancer Res. 2021 Jun 10. doi: 10.1158/1078-0432.CCR-21-0358. Online ahead of print. Clin Cancer Res. 2021. PMID: 34112710
Improvements in Radiographic Progression-Free Survival Stratified by ERG Gene Status in Metastatic Castration-Resistant Prostate Cancer Patients Treated with Abiraterone Acetate.
Attard G, de Bono JS, Logothetis CJ, Fizazi K, Mukherjee SD, Joshua AM, Schrijvers D, van den Eertwegh AJ, Li W, Molina A, Griffin TW, Kheoh T, Ricci DS, Zelinsky K, Rathkopf DE, Scher HI, Ryan CJ. Attard G, et al. Among authors: ricci ds. Clin Cancer Res. 2015 Apr 1;21(7):1621-7. doi: 10.1158/1078-0432.CCR-14-1961. Epub 2015 Jan 15. Clin Cancer Res. 2015. PMID: 25593303 Free PMC article. Clinical Trial.
Fewer bone disease events, improvement in bone remodeling, and evidence of bone healing with bortezomib plus melphalan-prednisone vs. melphalan-prednisone in the phase III VISTA trial in multiple myeloma.
Delforge M, Terpos E, Richardson PG, Shpilberg O, Khuageva NK, Schlag R, Dimopoulos MA, Kropff M, Spicka I, Petrucci MT, Samoilova OS, Mateos MV, Magen-Nativ H, Goldschmidt H, Esseltine DL, Ricci DS, Liu K, Deraedt W, Cakana A, van de Velde H, San Miguel JF. Delforge M, et al. Among authors: ricci ds. Eur J Haematol. 2011 May;86(5):372-84. doi: 10.1111/j.1600-0609.2011.01599.x. Epub 2011 Mar 30. Eur J Haematol. 2011. PMID: 21366694 Clinical Trial.